Biofarma · Aprovações da FDA · Ação
Mentari Therapeutics Inc is a biotechnology company engaged in the development of therapies for the prevention of migraine. Its product pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. The company's research and development activities…
Ativos registrados: MT-001
Catalisadores com data de MTRI, incluindo os decididos recentemente.
Nada agendado neste período.
Todos os eventos na fonte de MTRI, mais recentes primeiro.
Mentari Therapeutics reports Q3 2026 financial results post-merger with InMed
This 10-Q exhibit restates Mentari's financial position, operating expenses, and pipeline as of September 30, 2026. It recaps the completed merger with InMed Pharmaceuticals (closed Nov 6, 2026) and notes the anti-PACAP mAb MT-001 and other candidates remain in preclinical/early development with no new regulatory or clinical milestones announced.
Empresas do mesmo setor com valor de mercado mais próximo de MTRI.